医学界肿瘤频道|“仑伐替尼+帕博利珠单抗”，今日的“王炸”组合是联合疗法的明日之星( 三 )
[2] Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163-1173. doi:10.1016/S0140-6736(18)30207-1 [3] A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC). First Author: Andrew X. Zhu, Massachusetts General Hospital Cancer Center and Jiahui International Cancer Center, Boston, MA. ASCO 2020. [4] Sun, H.-C. (2020). Combination therapy with lenvatinib and anti-PD-1 antibodies for unresectable or advanced hepatocellular carcinoma: A real-world study, ASCO Virtual Scientific Program, American Society of Clinical Oncology. [5] Lee, C.-H. (2020). Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC), ASCO Virtual Scientific Program, American Society of Clinical Oncology. [6] Makker V, Rasco D, Vogelzang NJ, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20(5):711-718. doi:10.1016/S1470-2045(19)30020-8 [7] Taylor MH, Lee CH, Makker V, et al. Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors. J Clin Oncol. 2020;38(11):1154-1163. doi:10.1200/JCO.19.01598
推荐阅读
![[食品安全]《2020年春季开学学校食堂食品安全验收要点》出台](https://p0.ssl.qhimgs4.com/t01aee2417ca6e9c898.jpg)
- 健康报社|药师有话说｜陕西省肿瘤医院药学部主任曹舫：PARP抑制剂为卵巢癌患者提供用药新选择
- 癌症肿瘤|《黑豹》男主因癌去世，结肠癌为何钟爱中年人
- 肿瘤|远离肿瘤，从日常饮食做起！
- 癌症肿瘤|医生：癌症晚期患者生活中做到3点，可延长好几年寿命！
- 消化疾病,肿瘤|肠肿瘤并非无迹象，排便后瞅一眼，便便4种异常是“求救信号”
- 癌症肿瘤,胃炎|什么样的痛，会是癌症前变的“信号”？身上这4处，劝你别大意
- 癌症肿瘤,肺癌|医生确诊肺癌转移后带瘤生存6年，他的四句忠告，引人深思
- 癌症肿瘤,肿瘤|乳腺肿瘤“暴露”前， “马脚”很明显，日常多做5事，远离癌症
- 癌症肿瘤|吃辣椒是能致癌还是能防癌呢？
- 癌症肿瘤|远离肿瘤，从日常饮食做起！